Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio, Inc. develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Company news centers on its off-the-shelf cell-therapy pipeline, including prulacabtagene leucel, or prula-cel, a CD20-targeted CAR gamma delta T cell therapy, and ADI-212, a PSMA-targeted candidate.
Recurring updates also cover clinical and regulatory disclosures, operating and financial results, biotechnology conference participation, inducement equity grants under Nasdaq rules, shareholder voting matters, Nasdaq listing compliance, and capital-structure actions involving common stock.
Twist Bioscience (NASDAQ: TWST) and Adicet Bio (NASDA: ACET) have announced a collaboration aimed at accelerating the discovery of gamma delta T cell therapies targeting five undisclosed cancer-related antigens. Twist will utilize its proprietary antibody discovery technologies to aid in engineering immune cells with novel chimeric antigen receptors (CARs), enhancing Adicet's pipeline. The agreement includes an upfront technology licensing fee, clinical and regulatory milestones, and product royalties, emphasizing the partnership's potential in advancing T cell therapies for cancer treatment.
Adicet Bio, Inc. (Nasdaq: ACET) announced its participation in two virtual investor conferences in September 2021. The first is the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, where attendees can access a recorded presentation starting September 13 at 7:00 AM ET. The second event is the 2021 Cantor Virtual Global Healthcare Conference, featuring a fireside chat by CEO Chen Schor on September 27 at 10:00 AM ET. Live and archived audio webcasts will be available on Adicet Bio’s investor website.
Adicet Bio (Nasdaq: ACET) announced its Q2 2021 results, highlighting operational achievements and progress in its lead asset, ADI-001, for Non-Hodgkin's Lymphoma. The company expects to report interim data by 2021's end and has added a scientific advisory board to support its pipeline. Financially, R&D expenses rose to $10.6M, while G&A expenses decreased to $5.0M. The net loss was $10.9M, with a cash position of $208.7M expected to fund operations into mid-2023. Adicet's addition to the Russell 2000 Index could enhance investor visibility.
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology firm focused on allogeneic gamma delta T cell therapies, announced participation in three virtual investor conferences in August 2021. Key highlights include a fireside chat by CEO Chen Schor at the BTIG Virtual Biotechnology Conference on August 9 at 9:00 AM ET and a panel discussion on August 10 during the Wedbush PacGrow Healthcare Conference, as well as another fireside chat on August 11 at the Canaccord Genuity Annual Growth Conference. A webcast will be available on their investor website.
Adicet Bio (Nasdaq: ACET) announced the formation of a Scientific Advisory Board (SAB) on July 15, 2021. This board comprises distinguished experts in T cell biology, immunology, and oncology, who will provide strategic guidance for advancing Adicet’s lead asset, ADI-001, and its gamma delta T cell therapies. Key members include renowned doctors such as Alice Bertaina, Marco Davila, and Michael Kalos. The new board is expected to enhance the development of innovative cancer treatments, boosting Adicet's potential in the biotechnology sector.
Adicet Bio, Inc. (Nasdaq: ACET) announced its addition to the Russell 2000 Index, effective June 28, 2021. This inclusion reflects the significant progress the company has made in developing allogeneic gamma delta T cell therapies for cancer treatment. CEO Chen Schor expressed optimism that this recognition will enhance visibility for its gamma delta T cell product pipeline. Adicet is expected to release interim clinical data from its lead candidate ADI-001 later this year. The Russell Indexes are utilized widely by institutional investors, managing approximately $10.6 trillion in assets.
Adicet Bio, a biotechnology firm focused on innovative gamma delta T cell therapies, announced participation in two virtual investor conferences. The first is the UBS Global Healthcare Virtual Conference from May 24-26, where CEO Chen Schor will present on May 26 at 7:00 AM ET. The second event is the JMP Securities Life Sciences Conference on June 16-17, featuring a fireside chat with Schor on June 16 at 3:00 PM ET. Live webcasts will be available on their website, with replays accessible for 30 days post-event.
Adicet Bio (Nasdaq: ACET) reported a productive Q1 2021, highlighted by the successful $143.8 million capital raise and the initiation of a Phase 1 trial for ADI-001, targeting B Cell Non-Hodgkin's Lymphoma (NHL). The trial is positioned as the first allogeneic CAR gamma-delta T cell therapy to enter human trials, with interim data expected by late 2021. Despite increased R&D and G&A expenses totaling $17.3 million, the company holds $223.4 million in cash and marketable securities, providing a strong financial foundation through mid-2023.
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology firm focused on allogeneic gamma delta T cell therapies for cancer, will have its CEO, Chen Schor, present at the 7th Annual Truist Securities Life Sciences Summit on May 4, 2021, at 2:40 PM ET. A live audio webcast of the event will be available on their investors website, with an archived replay accessible for 30 days post-presentation. Adicet Bio is advancing engineered gamma delta T cells aimed at improving tumor targeting and immune response in patients.
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology firm, has announced that its President and CEO, Chen Schor, will participate in a panel on Gamma Delta CART-Cells at the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference on April 15, 2021. The panel, moderated by John Newman, Ph.D., will run from 1:00 PM to 1:55 PM ET. Adicet is focused on developing allogeneic gamma delta T cell therapies aimed at treating cancer and enhancing anti-tumor responses through innovative engineering techniques.